Skip to content

Study on the effect of percutaneous supraorbital nerve stimulation combined with drugs in the treatment of migraine

Efficacy of percutaneous supraorbital nerve stimulation combined with drugs in the treatment of migraine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081893
Enrollment
Unknown
Registered
2024-03-14
Start date
2024-03-15
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

1:Drug therapy
2:tSNS therapy
3:Drug+tSNS therapy

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of the International Classification of Headache Disorders (ICHD-3) for migraine. (2) Be between the ages of 18 and 65 and have at least 2 migraine attacks per month. (3) Be willing to participate in the test and sign written informed consent

Exclusion criteria

Exclusion criteria: (1) Patients with serious mental disorders and organ damage. (2) Implants containing cardiac pacemakers, defibrillators, metal devices or electrical devices. (3) Diagnosis of other primary or secondary headache diseases. (4) Pregnant, lactating or fertile without taking appropriate contraceptive measures.

Design outcomes

Primary

MeasureTime frame
Pain-free after 2 hours ;Freedom from the most bothersome symptom at 2 hours;

Secondary

MeasureTime frame
Headache relief at 2 hours;

Countries

China

Contacts

Public ContactTan Ge

The First Affiliated Hospital of Chongqing Medical University

17358575477@163.com+86 158 2393 2812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026